Class Action Lawsuit Filed Against Regeneron Pharmaceuticals: What Does It Mean for Investors and the World?
On January 27, 2025, The Schall Law Firm, a leading national shareholder rights litigation firm, announced a class action lawsuit against Regeneron Pharmaceuticals, Inc. (Regeneron or the Company) for alleged violations of the Securities Exchange Act of 1934. The lawsuit, which was filed in the Southern District of New York, accuses Regeneron of violating Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5 during the period from November 2, 2023, to October 30, 2024 (the Class Period).
Impact on Regeneron Investors
The lawsuit alleges that Regeneron made false and misleading statements regarding the safety and efficacy of its Eylea drug, which is used to treat various eye conditions. The company is accused of downplaying the risks associated with the drug and failing to disclose material information about the potential for adverse events. The lawsuit seeks to recover damages for investors who purchased Regeneron’s securities during the Class Period.
Implications for the World
The lawsuit against Regeneron is significant because it highlights the importance of transparency and accuracy in the pharmaceutical industry. Regeneron’s alleged misrepresentations regarding the safety and efficacy of its drug could have serious consequences for patients and healthcare providers. The case also underscores the role of shareholder rights litigation in holding companies accountable for their actions and ensuring that investors are informed about material information.
Further Information
- The Schall Law Firm’s press release on the lawsuit can be found at
- Regeneron’s SEC filings, including its annual reports and quarterly reports, can be accessed on the company’s Investor Relations website at
It is important to note that the filing of a class action lawsuit is not a guarantee of any outcome, and shareholders are encouraged to consult with their own investment advisors before taking any action based on this information.
Conclusion
The class action lawsuit against Regeneron Pharmaceuticals is a reminder of the importance of transparency and accuracy in the pharmaceutical industry. The alleged misrepresentations regarding the safety and efficacy of Regeneron’s Eylea drug could have serious consequences for patients and healthcare providers, as well as for investors. As the case unfolds, it will be important to stay informed about developments and to consult with financial advisors for guidance.
Regeneron investors who purchased the company’s securities during the Class Period are encouraged to contact The Schall Law Firm to discuss their legal rights and potential remedies. The lawsuit seeks to recover damages for investors who may have been harmed by Regeneron’s alleged violations of securities laws.
The outcome of this case could have significant implications for the pharmaceutical industry and for investors. It is a reminder that companies must be transparent and accurate in their public disclosures, and that shareholder rights litigation can play an important role in holding them accountable.
